Agios Pharmaceuticals (NASDAQ:AGIO) Rating Reiterated by Royal Bank of Canada

Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “outperform” rating restated by equities researchers at Royal Bank of Canada in a report released on Thursday, Benzinga reports. They presently have a $55.00 target price on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would suggest a potential upside of 20.77% from the company’s current price.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $51.33.

Agios Pharmaceuticals Trading Down 0.3 %

Shares of AGIO opened at $45.54 on Thursday. Agios Pharmaceuticals has a 12-month low of $19.80 and a 12-month high of $50.35. The firm has a market cap of $2.59 billion, a PE ratio of -7.21 and a beta of 0.75. The company’s 50 day simple moving average is $45.59 and its 200-day simple moving average is $38.93.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The business had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The company’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.51) earnings per share. As a group, equities research analysts forecast that Agios Pharmaceuticals will post -4.85 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.93% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors have recently bought and sold shares of AGIO. Nordea Investment Management AB increased its holdings in shares of Agios Pharmaceuticals by 13.0% during the 1st quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company’s stock valued at $7,824,000 after acquiring an additional 30,764 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in shares of Agios Pharmaceuticals by 79.2% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 523,166 shares of the biopharmaceutical company’s stock worth $11,651,000 after buying an additional 231,164 shares during the last quarter. Caxton Associates LP bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth $1,087,000. Norges Bank bought a new position in Agios Pharmaceuticals in the 4th quarter worth $6,826,000. Finally, Vanguard Group Inc. lifted its position in Agios Pharmaceuticals by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company’s stock worth $123,096,000 after acquiring an additional 59,851 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.